Liquid Biopsy Market Size and Share

The global liquid biopsy market was valued at US$ 13.95 Billion in 2023, and is expected to register a CAGR of 7.6% over the forecast period and reach US$ 26.9 Bn in 2032.

Liquid biopsy is a laboratory test conducted on a sample of blood, urine, or other body fluid to identify and detect cancer cells from a tumor or small pieces of Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA), or by using other molecules released by tumor cells into fluids in the body of a person. It is a simple and minimally-invasive alternative to surgical and traditional tissue biopsies and has emerged as a revolutionary diagnostic approach, offering real-time detection of biomarkers in bodily fluids, primarily blood.